HRP20191994T1 - Formulacije ketorolaka spremne za uporabu - Google Patents
Formulacije ketorolaka spremne za uporabu Download PDFInfo
- Publication number
- HRP20191994T1 HRP20191994T1 HRP20191994TT HRP20191994T HRP20191994T1 HR P20191994 T1 HRP20191994 T1 HR P20191994T1 HR P20191994T T HRP20191994T T HR P20191994TT HR P20191994 T HRP20191994 T HR P20191994T HR P20191994 T1 HRP20191994 T1 HR P20191994T1
- Authority
- HR
- Croatia
- Prior art keywords
- ketorolac
- pharmaceutically acceptable
- pharmaceutical preparation
- agent
- acceptable salt
- Prior art date
Links
- 229960004752 ketorolac Drugs 0.000 title claims 12
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 title claims 12
- 239000000203 mixture Substances 0.000 title claims 8
- 238000009472 formulation Methods 0.000 title claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 229920000858 Cyclodextrin Polymers 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims 5
- 238000002360 preparation method Methods 0.000 claims 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 3
- 230000036592 analgesia Effects 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000008121 dextrose Substances 0.000 claims 3
- 238000001802 infusion Methods 0.000 claims 3
- 238000007911 parenteral administration Methods 0.000 claims 3
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 2
- 230000000202 analgesic effect Effects 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 239000001116 FEMA 4028 Substances 0.000 claims 1
- 239000005715 Fructose Substances 0.000 claims 1
- 229930091371 Fructose Natural products 0.000 claims 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000002535 acidifier Substances 0.000 claims 1
- 230000003113 alkalizing effect Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims 1
- 229960004853 betadex Drugs 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- 239000001110 calcium chloride Substances 0.000 claims 1
- 229910001628 calcium chloride Inorganic materials 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000008139 complexing agent Substances 0.000 claims 1
- 239000006184 cosolvent Substances 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003792 electrolyte Substances 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 150000002170 ethers Chemical class 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 229960004384 ketorolac tromethamine Drugs 0.000 claims 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical group OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 229910001629 magnesium chloride Inorganic materials 0.000 claims 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 239000000014 opioid analgesic Substances 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 239000001103 potassium chloride Substances 0.000 claims 1
- 235000011164 potassium chloride Nutrition 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 239000000811 xylitol Substances 0.000 claims 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 1
- 229960002675 xylitol Drugs 0.000 claims 1
- 235000010447 xylitol Nutrition 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (16)
1. Farmaceutski pripravak za parenteralnu primjenu koja sadrži: vodena otopina koji sadrži ketorolak ili njegovu farmaceutski prihvatljivu sol u količini od 0.1 mg/mL do 10 mg/mL; i farmaceutski prihvatljivi ekscipijent odabran iz skupine sastavljen od trehaloze, bezvodnog ili hidratnog oblika natrij klorida, dekstroze, saharoze, ksilitola, fruktoze, glicerola, sorbitola, kalij klorida, manoze, kalcij klorida i magnezij klorida;
pri čemu pripravak ne sadrži alkohol;
i pri čemu pripravak zadržava najmanje 90% količine ketorolaka ili njegove farmaceutski prihvatljive soli nakon skladištenja 6 mjeseci.
2. Farmaceutski pripravak sukladno patentnom zahtjevu 1, koja zadržava najmanje 95% količine ketorolaka ili njegove farmaceutski prihvatljive soli nakon skladištenja od 1 godine.
3. Farmaceutski pripravak sukladno patentnom zahtjevu 1 ili 2, koja ima pH od 4.5 do 8.5.
4. Farmaceutski pripravak sukladno bilo kojem patentnom zahtjevu, pri čemu je farmaceutski prihvatljiva sol ketorolak trometamin.
5. Farmaceutski pripravak sukladno bilo kojem patentnom zahtjevu, koja dalje sadrži kootapalo i/ili regulator pH odabran iz skupine sastavljene od kiseline ili baze
6. Farmaceutski pripravak sukladno bilo kojem patentnom zahtjevu, koja je sadržan u farmaceutski prihvatljivom spremniku odabranom iz skupine sastavljene od intravenskih vrećica i boca.
7. Farmaceutski pripravak sukladno bilo kojem patentnom zahtjevu, pri čemu ekscipijent nadalje obuhvaća sredstvo za pospješivanje otapanja, antioksidans, sredstvo za puferiranje, sredstvo za zakiseljavanje, sredstvo za pojačavanje kompleksa, fiziološka otopina, dekstrozu, pomoćno sredstvo za liofilizaciju, potpora, sredstvo za povećanje volumena, sredstva za stabiliziranje, elektrolita, drugi terapeutski agens, alkalizacijsko sredstvo, sredstvo protiv gljivica, ili njihove kombinacije.
8. Farmaceutski pripravak sukladno patentnom zahtjevu 1, pri čemu farmaceutski prihvatljivi ekscipijent nadalje obuhvaća sredstvo za toniziranje, trehalozu, površinski aktivno sredstvo, aminokiselinu, ili karboksilnu kiselinu.
9. Farmaceutski pripravak sukladno patentnom zahtjevu 1, pri čemu ekscipijens nadalje obuhvaća ciklodekstrin, pri čemu je ciklodekstrin betaciklodekstrin, pri čemu je ciklodekstrin sulfoalkilirani eter ciklodekstrin, pri čemu se formulacija razrjeđuje s farmaceutski prihvatljivim vodenim tekućim nosačem na sobnoj temperaturi s beznačajnim taloženje ketorolaka.
10. Farmaceutski pripravak sukladno bilo kojem patentnom zahtjevu, koji nadalje sadrži opioidni analgetik.
11. Farmaceutski pripravak sukladno patentnom zahtjevu 1 koja sadrži: od 0.1 mg/ml do 1 mg/ml ketorolaka ili njegove farmaceutski prihvatljive soli od 0.1 % do 3% dekstroze ili od 0.1% do 10% trehaloze; pri čemu se pripravak nalazi u fleksibilnoj intravenskoj vrećici; pri čemu formulacija sadrži pH od 6.0 do 7.5; i pri čemu formulacija zadržava najmanje 95% količine ketorolaka ili njegove farmaceutski prihvatljive soli nakon skladištenja godinu dana.
12. Farmaceutski pripravak sukladno bilo kojem prethodnom patentnom zahtjevu, naznačen time da se koristi u postupku liječenja ketorolakom kojim se može liječiti stanje kod pacijenta koji ima uvjete za liječenje ketorolakom sukladno bilo kojem od prethodnih zahtjeva.
13. Farmaceutski pripravak sukladno patentnom zahtjevu 12, pri čemu je postupak za pružanje analgezije, uz smanjenje količine opioida i/ili NSAIL-ova koji se daju pacijentu, pri čemu postupak sadrži parenteralno davanje pripravka sukladno bilo kojem od prethodnih zahtjeva kontinuiranom infuzijom pacijentu kome je to nužno.
14. Farmaceutski pripravak sukladno patentnom zahtjevu 12 ili 13, pri čemu je postupak za pružanje analgezije pacijentu kome je to nužno i uključuje primjenu bolusne doze ketorolaka da bi se postigla brza analgetička reakcija, praćena kontinuiranom infuzijom pripravka sukladno bilo kojem od prethodnih zahtjeva radi zadržavanja analgetičke reakcije.
15. Farmaceutski pripravak sukladno patentnom zahtjevu 12, pri čemu stanje koje se može tretirati keterolakom analgezija i postupak sadrži parenteralnu primjenu kompozicije kontinuiranom infuzijom pacijentu kome je to nužno.
16. Postupak pripreme farmaceutskog pripravka koji uključuje kombiniranje ketorolaka ili njegove farmaceutski prihvatljive soli s vodenom otopinom i ekscipijentom, čime se dobiva sastav bilo kojeg od prethodnih zahtjeva.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40538410P | 2010-10-21 | 2010-10-21 | |
| US201161481602P | 2011-05-02 | 2011-05-02 | |
| PCT/US2011/057284 WO2012054831A2 (en) | 2010-10-21 | 2011-10-21 | Ready to use ketorolac formulations |
| EP11835216.0A EP2616064B1 (en) | 2010-10-21 | 2011-10-21 | Ready to use ketorolac formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191994T1 true HRP20191994T1 (hr) | 2020-02-07 |
Family
ID=45973506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191994TT HRP20191994T1 (hr) | 2010-10-21 | 2019-11-05 | Formulacije ketorolaka spremne za uporabu |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US9421191B2 (hr) |
| EP (3) | EP3632432B1 (hr) |
| JP (1) | JP6013346B2 (hr) |
| KR (4) | KR102114568B1 (hr) |
| CN (2) | CN108703948A (hr) |
| CA (1) | CA2814805C (hr) |
| CY (1) | CY1122516T1 (hr) |
| DK (1) | DK2616064T3 (hr) |
| ES (2) | ES2753981T3 (hr) |
| HR (1) | HRP20191994T1 (hr) |
| HU (1) | HUE045889T2 (hr) |
| LT (1) | LT2616064T (hr) |
| MX (1) | MX346879B (hr) |
| PL (1) | PL2616064T3 (hr) |
| PT (1) | PT2616064T (hr) |
| RS (1) | RS59526B1 (hr) |
| SI (1) | SI2616064T1 (hr) |
| WO (1) | WO2012054831A2 (hr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012054831A2 (en) | 2010-10-21 | 2012-04-26 | Rtu Pharmaceuticals, Llc | Ready to use ketorolac formulations |
| US10098872B1 (en) | 2013-07-22 | 2018-10-16 | William Bradley Worthington | Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief |
| US11559521B2 (en) * | 2013-07-22 | 2023-01-24 | William Bradley Worthington | Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief |
| US11992484B2 (en) | 2013-07-22 | 2024-05-28 | Hutchison Health, Llc | Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief |
| US11992485B2 (en) | 2013-07-22 | 2024-05-28 | Hutchison Health, Llc | Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief |
| CA2919892C (en) | 2013-08-12 | 2019-06-18 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| CN103830171B (zh) * | 2014-03-04 | 2015-11-18 | 鲁南制药集团股份有限公司 | 一种酮咯酸氨丁三醇注射液及其制备方法 |
| US9707184B2 (en) | 2014-07-17 | 2017-07-18 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| EP3209282A4 (en) | 2014-10-20 | 2018-05-23 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| EP4008319A1 (en) * | 2015-11-25 | 2022-06-08 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| IT201600075246A1 (it) * | 2016-07-19 | 2018-01-19 | Jointherapeutics S R L | Composizioni comprendenti una matrice polisaccaridica per il rilascio controllato di principi attivi. |
| WO2018209150A1 (en) * | 2017-05-10 | 2018-11-15 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| FR3101917B1 (fr) | 2019-10-09 | 2022-07-15 | Ifp Energies Now | Système de refroidissement à radiateur unique |
| CN110812325B (zh) * | 2019-11-13 | 2022-04-05 | 鲁南制药集团股份有限公司 | 一种提高酮咯酸氨丁三醇注射液存储稳定性的方法 |
| CN113679676A (zh) * | 2020-05-19 | 2021-11-23 | 南京海融医药科技股份有限公司 | 一种左酮咯酸的药物组合物及其制备方法 |
| CN114159384B (zh) * | 2021-02-07 | 2023-04-07 | 南京锐志生物医药有限公司 | 一种化学性质稳定的低刺激性酮咯酸氨丁三醇注射液 |
| EP4360622A1 (en) * | 2021-06-24 | 2024-05-01 | Shanghai Aurora Biotechnology Co., Ltd. | Ketorolac liquid composition, preparation method therefor, and application thereof |
| CN113384524A (zh) * | 2021-07-05 | 2021-09-14 | 四川尚锐生物医药有限公司 | 一种稳定的酮咯酸氨丁三醇注射液的制备方法 |
| CN114191384A (zh) * | 2021-12-20 | 2022-03-18 | 成都倍特药业股份有限公司 | 一种即用型酮咯酸氨丁三醇和氢溴酸依他佐辛组合液体制剂 |
| CN114432240A (zh) * | 2022-03-04 | 2022-05-06 | 郑州市中心医院 | 一种稳定不刺激的酮咯酸氨丁三醇注射液及其制备方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4089969A (en) | 1976-07-14 | 1978-05-16 | Syntex (U.S.A.) Inc. | 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof |
| US5214052A (en) | 1987-07-28 | 1993-05-25 | Mitsubishi Kasei Corporation | Method for dissolving arginineamides and pharmaceutical compositions containing them |
| EP0948965B1 (en) | 1997-07-11 | 2004-06-02 | Toray Industries, Inc. | Stable medicinal compositions containing 4,5-epoxymorphinane derivatives |
| US6608073B1 (en) | 1998-10-14 | 2003-08-19 | New Millennium Pharmaceutical Research, Inc. | Intranasal codeine for the rapid suppression of cough and rapid relief of pain |
| WO2000057851A2 (en) | 1999-03-26 | 2000-10-05 | Pozen Inc. | High potency dihydroergotamine compositions |
| US20040022787A1 (en) * | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
| US6509027B2 (en) * | 2001-02-12 | 2003-01-21 | Supergen, Inc. | Injectable pharmaceutical composition comprising coated particles of camptothecin |
| US20030191187A1 (en) * | 2002-04-01 | 2003-10-09 | Lee Fang Yu | Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same |
| US20040105881A1 (en) | 2002-10-11 | 2004-06-03 | Gregor Cevc | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin |
| DK2368554T3 (en) | 2003-04-08 | 2015-01-26 | Progenics Pharm Inc | A pharmaceutical composition comprising methylnaltrexone |
| US20070049552A1 (en) | 2003-04-14 | 2007-03-01 | Babu Manoj M | Fluoroquinolone formulations and methods of making and using the same |
| US20080317681A1 (en) | 2003-07-11 | 2008-12-25 | Petros Gebreselassie | Compositions containing a stain removing complex, and methods of making and using the same |
| US20050266031A1 (en) | 2004-05-25 | 2005-12-01 | Jay Dickerson | Pharmaceutical suspension composition |
| CA2584184A1 (en) | 2004-10-15 | 2006-04-27 | Seo Hong Yoo | Methods and compositions for reducing toxicity of a pharmaceutical compound |
| US8148356B2 (en) | 2005-08-24 | 2012-04-03 | Cumberland Pharmaceuticals, Inc. | Acetylcysteine composition and uses therefor |
| MX2008002177A (es) | 2005-09-01 | 2008-04-22 | Baxter Healthcare Sa | Formulacion de argatroban. |
| US20070142478A1 (en) | 2005-12-21 | 2007-06-21 | Erning Xia | Combination antimicrobial composition and method of use |
| CA2635797C (en) | 2006-02-09 | 2015-03-31 | Macusight, Inc. | Stable formulations, and methods of their preparation and use |
| DOP2007000055A (es) * | 2006-04-10 | 2007-10-31 | Senosiain S A De C V Lab | Composición farmaceutica que comprende un analgésico y vitaminas |
| CN101484006A (zh) | 2006-04-18 | 2009-07-15 | Ekr治疗公司 | 预混和的、立即可用的ⅳ推注组合物和使用方法 |
| US20100010046A1 (en) | 2006-06-12 | 2010-01-14 | Ironwood Pharmaceuticals, Inc. | Pharmaceutical formulation for parenteral administration |
| CA2656087A1 (en) | 2006-06-29 | 2008-01-10 | Schering Corporation | Sugar-free storage-stable antihistaminic syrups |
| US20080014274A1 (en) | 2006-07-14 | 2008-01-17 | Wyeth | Enhanced stability phenylephrine liquid compositions |
| TWI489984B (zh) | 2006-08-04 | 2015-07-01 | Wyeth Corp | 用於非經腸道傳輸化合物之配方及其用途 |
| US20080057023A1 (en) | 2006-08-29 | 2008-03-06 | Chynn Emil W | Oxygenated ophthalmic composition |
| CA2669727C (en) | 2006-09-27 | 2014-10-28 | Eagle Pharmaceuticals, Inc. | Alcohol free formulation of argatroban |
| KR100836624B1 (ko) | 2006-12-08 | 2008-06-10 | 한국전자통신연구원 | 가변 고속 푸리에 변환 장치 및 그 방법 |
| US20080312154A1 (en) | 2007-06-15 | 2008-12-18 | Barbara Lee Peterlin | Administration of adipocytokine and adiponectin for treating headache and methods of diagnosing headache by measuring adiponectin |
| DK2197429T3 (en) | 2007-09-03 | 2016-05-30 | Nanotherapeutics Inc | Particulate compositions for delivery of poorly soluble drugs |
| WO2009087658A2 (en) * | 2007-11-07 | 2009-07-16 | Sun Pharma Advanced Research Company Limited | Composition suitable for parenteral administration |
| CA2705733C (en) | 2007-11-13 | 2015-02-03 | Cadence Pharmaceuticals | Reduced dose intravenous acetaminophen |
| US20090239836A1 (en) | 2008-03-24 | 2009-09-24 | Mary Lee Ciolkowski | Multifunctional Ophthalmic Compositions |
| US8956636B2 (en) * | 2008-04-18 | 2015-02-17 | Warsaw Orthopedic, Inc. | Methods and compositions for treating postoperative pain comprosing ketorolac |
| US7635773B2 (en) * | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
| TWI397038B (zh) * | 2008-11-05 | 2013-05-21 | Au Optronics Corp | 使用半源極驅動架構之顯示面板及其顯示資料供應方法 |
| CA3225438A1 (en) * | 2010-07-19 | 2012-01-26 | Remedy Pharmaceuticals, Inc. | Methods of intravenous adminstration of glyburide and other drugs |
| WO2012012640A1 (en) | 2010-07-21 | 2012-01-26 | Cumberland Pharmaceuticals, Inc. | Acetycysteine compositions and methods of use thereof |
| WO2012054831A2 (en) | 2010-10-21 | 2012-04-26 | Rtu Pharmaceuticals, Llc | Ready to use ketorolac formulations |
-
2011
- 2011-10-21 WO PCT/US2011/057284 patent/WO2012054831A2/en active Application Filing
- 2011-10-21 KR KR1020187027505A patent/KR102114568B1/ko active IP Right Grant
- 2011-10-21 ES ES11835216T patent/ES2753981T3/es active Active
- 2011-10-21 CN CN201810988217.6A patent/CN108703948A/zh active Pending
- 2011-10-21 SI SI201131812T patent/SI2616064T1/sl unknown
- 2011-10-21 PL PL11835216T patent/PL2616064T3/pl unknown
- 2011-10-21 ES ES19189949T patent/ES2933198T3/es active Active
- 2011-10-21 MX MX2013004393A patent/MX346879B/es active IP Right Grant
- 2011-10-21 US US13/278,703 patent/US9421191B2/en active Active
- 2011-10-21 PT PT118352160T patent/PT2616064T/pt unknown
- 2011-10-21 KR KR1020207013936A patent/KR102307601B1/ko active IP Right Grant
- 2011-10-21 KR KR1020137009935A patent/KR20140012029A/ko active Search and Examination
- 2011-10-21 HU HUE11835216A patent/HUE045889T2/hu unknown
- 2011-10-21 DK DK11835216T patent/DK2616064T3/da active
- 2011-10-21 LT LT11835216T patent/LT2616064T/lt unknown
- 2011-10-21 KR KR1020197019855A patent/KR20190085561A/ko not_active Application Discontinuation
- 2011-10-21 CA CA2814805A patent/CA2814805C/en active Active
- 2011-10-21 EP EP19189949.1A patent/EP3632432B1/en active Active
- 2011-10-21 CN CN201180050372XA patent/CN103167800A/zh active Pending
- 2011-10-21 RS RS20191421A patent/RS59526B1/sr unknown
- 2011-10-21 JP JP2013535115A patent/JP6013346B2/ja active Active
- 2011-10-21 EP EP11835216.0A patent/EP2616064B1/en active Active
- 2011-10-21 EP EP22195395.3A patent/EP4190327A1/en active Pending
-
2016
- 2016-07-15 US US15/211,560 patent/US9962371B2/en active Active
-
2018
- 2018-04-06 US US15/946,865 patent/US10278959B2/en active Active
- 2018-12-07 US US16/213,250 patent/US11116750B2/en active Active
-
2019
- 2019-11-05 HR HRP20191994TT patent/HRP20191994T1/hr unknown
- 2019-11-06 CY CY20191101153T patent/CY1122516T1/el unknown
-
2021
- 2021-08-09 US US17/396,890 patent/US20220023260A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191994T1 (hr) | Formulacije ketorolaka spremne za uporabu | |
| ES2911207T3 (es) | Composiciones de insulina de acción rápida | |
| HRP20191777T1 (hr) | Vodena farmaceutska formulacija tapentadola za oralnu primjenu | |
| ES2223549T3 (es) | Formulacion que contiene moxifloxacino y sal comun. | |
| DK2387389T3 (en) | Composition for oral transmucosal administration of analgesic or antispasmodic molecules | |
| US20230181502A1 (en) | Aqueous formulation comprising paracetamol and ibuprofen | |
| JP5993442B2 (ja) | 医薬組成物 | |
| EP2825039A2 (en) | Injectable ibuprofen formulation | |
| CA2814057A1 (en) | Intravenous composition comprising paracetamol and ibuprofen | |
| TWI718158B (zh) | 藥學組成物 | |
| US9072661B2 (en) | Injectable ibuprofen formulation | |
| US20240024481A1 (en) | Injectable ibuprofen formulation | |
| ES2866636T3 (es) | Composiciones farmacéuticas que comprenden paracetamol y proceso para preparar las mismas | |
| CN103417473B (zh) | 一种阿达帕林凝胶剂及其制备方法 | |
| JP2010132608A (ja) | 医薬用水性液状組成物 | |
| WO2013124498A1 (es) | Composición farmacéutica de ibuprofeno y tramadol para inyección | |
| ES2943933T3 (es) | Colirios de palonosetrón para el tratamiento o la prevención de náuseas y vómitos | |
| CN103989640B (zh) | 奥硝唑静脉给药制剂及其制备方法 | |
| WO2009157010A1 (en) | An intravenous drug delivery system | |
| JP2019085338A (ja) | ボルテゾミブを含有する凍結乾燥医薬組成物 | |
| RU2014148062A (ru) | Инъекционная фармацевтическая композиция декскетопрофена и трамадола | |
| CN104414963A (zh) | 一种含左西孟旦的药物组合物 | |
| CN104379134A (zh) | 肠外艾司洛尔剂型 | |
| CA2994748A1 (en) | Pharmaceutical composition comprising sumatripan for treating migraine | |
| ES2363395A1 (es) | Composición farmacéutica líquida de rivastigmina o de una de sus sales de adición de ácido para la administración por vía oral. |